Illumina Raises Full-Year Guidance After Q2 Revenue Climbs 9.5%
The genomics company reported second-quarter revenue of $1.16 billion and lifted its fiscal 2026 outlook on continued demand for its NovaSeq X sequencing platform.
Strong Quarter Prompts Guidance Lift
Illumina reported second-quarter revenue of $1.16 billion, representing a 9.5% increase from the year-ago period, according to an 8-K filing submitted July 30, 2026. The San Diego-based genomics company posted organic revenue growth of 8.1% excluding currency impacts, acquisitions, and China operations (8-K filing, 2026-07-30).
The results prompted management to raise its full-year revenue guidance to $4.60-$4.64 billion from a prior range of $4.52-$4.62 billion. The company also increased its rest-of-world organic revenue growth outlook to greater than 5% from a previous 2%-4% (8-K filing, 2026-07-30).
"Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications," CEO Jacob Thaysen said in the press release (8-K filing, 2026-07-30).
Profitability and Cash Generation
Illumina reported GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% for the quarter. GAAP diluted earnings per share came in at $1.35, while non-GAAP diluted EPS reached $1.31 (8-K filing, 2026-07-30).
For the full year, the company maintained its non-GAAP operating margin guidance at 23.4%-23.6% while raising its non-GAAP diluted EPS outlook to $5.30-$5.40 from $5.15-$5.30 (8-K filing, 2026-07-30).
Free cash flow declined to $162 million in the quarter from $204 million in the prior-year period, with operating cash flow of $201 million partially offset by $39 million in capital expenditures. The company held $1.17 billion in cash, cash equivalents, and short-term investments at quarter-end (8-K filing, 2026-07-30).
NovaSeq Demand and Strategic Priorities
Thaysen highlighted sustained demand for the NovaSeq X platform, noting the company's efforts to expand workflow and multiomics capabilities. "Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem," he stated (8-K filing, 2026-07-30).
The filing's forward-looking statements section outlined multiple risk factors, including uncertainty regarding China's unreliable entities list designation, integration challenges related to the SomaLogic acquisition, tariff uncertainties, and ongoing litigation risks connected to the GRAIL acquisition (8-K filing, 2026-07-30).
MarginX data shows recent insider activity including awards to Keith A. Meister (142 shares) and Scott B. Ullem (167 shares), alongside a sale of 615 shares by Scott M. Davies.
Market Context
With a market capitalization of approximately $31 billion and shares last trading at $205.10, Illumina continues to position itself as what it describes as "a global leader in DNA sequencing and array-based technologies" serving research, clinical, and applied markets (8-K filing, 2026-07-30).
The company scheduled a conference call for 1:30 p.m. Pacific Time on July 30, 2026, to discuss the results. Upcoming Federal Reserve rate decisions are scheduled for September 16 and October 28, 2026, according to MarginX data.
This article was generated by MarginX from the 8-K filing on 2026-07-30. It is not investment advice.